The study plans to evaluate the impact of the Modified Mediterranean Diet on the biodiversity of the intestinal microbiota (the set of physiological bacteria present at the intestinal level) in patients suffering from metastatic colorectal cancer undergoing chemotherapy treatment +/- biological agent, comparing the microbiota with that of patients following a Western or standard diet.
Specifically, as well demonstrated in clinical studies, there are populations of bacteria that play a role in protecting the intestinal barrier and whose proliferation could be promoted by the Modified Mediterranean Diet.
The study also intends to evaluate the influence of the microbiome on the clinical progress of the disease in terms of side effects and quality of life.
Eastern Cooperative Oncology Group performance status (ECOG): 0 or 1;
Age ≥ 18;
Diagnosis of metastatic colorectal cancer, documented histologically and radiologically according to RECIST 1:1 criteria;
1st line chemotherapy treatment +/- biological agent (anti-EGFR, anti-VEGF);
Previous oncological medical therapies;
Indication for parenteral and/or enteral nutrition;
MUST score > 2.
Azienda Socio Sanitaria della Brianza
Lead sponsor
University of Milano Bicocca
Collaborator